{"id":"W4324136914","doi":"10.1200/jco.2023.41.6_suppl.tps591","title":"Phase 2 KEYNOTE-057 cohort C: Pembrolizumab (pembro) with vibostolimab or favezelimab for patients (pts) with high-risk (HR) bacillus Calmette-Guérin (BCG)-unresponsive non–muscle-invasive bladder cancer (NMIBC).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Pembrolizumab; Cohort; Bladder cancer; Oncology; Internal medicine; Cancer; Urology; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002312285,0.0012731,0.0009649723,0.0003499288,0.0005258893,0.001012197,0.001270558,0.001671151,0.009892846],"category_scores_gemma":[0.001106917,0.0004839577,0.001793176,0.0003762934,0.0004396704,0.0009053616,0.0007360416,0.003410209,0.001994947],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001703649,"about_ca_system_score_gemma":0.00336073,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00199217,"about_ca_topic_score_gemma":0.005263341,"domain_scores_codex":[0.99958,0.0001540135,0.00002639404,0.00007825936,0.00005885469,0.0001024131],"domain_scores_gemma":[0.9990983,0.0000709497,0.0002056484,0.00006377152,0.0001071908,0.0004541056],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6765065,0.0609955,0.01765912,0.002427465,0.002831992,0.0004567483,0.0003035907,0.003707966,0.04815692,0.001379675,0.06418082,0.1213937],"study_design_scores_gemma":[0.6308616,0.2928953,0.03049597,0.0002929497,0.00121373,0.0006909301,0.0001233702,0.001269355,0.006964087,0.0006694861,0.0344727,0.00005056291],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9020635,0.004918417,0.002384693,0.002851949,0.000584921,0.03686405,0.03646348,0.0004475695,0.01342145],"genre_scores_gemma":[0.8713968,0.004519699,0.008129076,0.009479525,0.0005772734,0.03383942,0.05743627,0.0001419499,0.01447994],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009892846,"threshold_uncertainty_score":0.03309488,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06530937548472666,"score_gpt":0.4273297818045215,"score_spread":0.3620204063197949,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}